Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

[1]  R. Wing,et al.  A prospective study of effects of weight cycling on cardiovascular risk factors. , 1995, Archives of internal medicine.

[2]  Jonathan Krakoff,et al.  Four‐Year Weight Losses in the Look AHEAD Study: Factors Associated With Long‐Term Success , 2011, Obesity.

[3]  A. Wirth,et al.  Long-term weight loss with sibutramine: a randomized controlled trial. , 2001, JAMA.

[4]  N. N. Available.  World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.

[5]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[6]  T. Wadden,et al.  Randomized trial of lifestyle modification and pharmacotherapy for obesity. , 2005, The New England journal of medicine.

[7]  T. J. Schulz,et al.  Combined serum amylase and lipase determinations for diagnosis of suspected acute pancreatitis. , 1993, Clinical chemistry.

[8]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[9]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[10]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[11]  L. Blonde,et al.  The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies , 2009, Diabetes, obesity & metabolism.

[12]  P. Vague,et al.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. , 1999, The American journal of medicine.

[13]  L. J. Duncan,et al.  Comparison of continuous and intermittent anorectic therapy in obesity. , 1968, British medical journal.

[14]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[15]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .

[16]  A. Astrup,et al.  Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. , 2004, Obesity research.

[17]  Alan Bauck,et al.  Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. , 2008, JAMA.

[18]  K. Fujioka,et al.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. , 1999, The American journal of clinical nutrition.

[19]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[20]  J. Mundt,et al.  Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology. , 2010, Journal of psychiatric research.

[21]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[22]  Deborah F Tate,et al.  A self-regulation program for maintenance of weight loss. , 2006, The New England journal of medicine.

[23]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[24]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[25]  J. Buse,et al.  Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies , 2011, Diabetes & vascular disease research.

[26]  T. Wadden,et al.  Lifestyle Modification for Obesity: New Developments in Diet, Physical Activity, and Behavior Therapy , 2012, Circulation.

[27]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[28]  B. Regnier,et al.  Good clinical practice , 1990, European Journal of Clinical Microbiology and Infectious Diseases.

[29]  T. Wadden,et al.  Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. , 1999, Obesity research.

[30]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  R. Wing,et al.  Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. , 1993, The Journal of clinical endocrinology and metabolism.

[32]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[33]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.